Leiv Lea
Net Worth

Last updated:

What is Leiv Lea net worth?

The estimated net worth of Mr. Leiv Lea is at least $3,479,733 as of 14 Dec 2022. He owns shares worth $684,843 as insider and has received compensation worth at least $2,794,890 in Corvus Pharmaceuticals, Inc..

What is the salary of Leiv Lea?

Mr. Leiv Lea salary is $399,270 per year as Chief Financial Officer in Corvus Pharmaceuticals, Inc..

How old is Leiv Lea?

Mr. Leiv Lea is 71 years old, born in 1954.

What stocks does Leiv Lea currently own?

As insider, Mr. Leiv Lea owns shares in one company:

Company Title Shares Price per share Total value
Corvus Pharmaceuticals, Inc. (CRVS) Chief Financial Officer 133,238 $5.14 $684,843

What does Corvus Pharmaceuticals, Inc. do?

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with either advanced or refractory renal cell cancer. Its preclinical stage products include CPI-182, an antibody designed to block inflammation and myeloid suppression; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals for the development its pipeline of targeted investigational medicines. The company was incorporated in 2014 and is based in Burlingame, California.

CRVS logo
CRVS
Corvus Pharmaceuticals, Inc.
$5.14

Leiv Lea insider trading

Corvus Pharmaceuticals, Inc.

Transaction Date Security Shares Price per share Total value Source
Purchase
Common Stock 4,000 $0.84 $3,364
Purchase
Common Stock 30,000 $0.74 $22,290
Purchase
Common Stock 13,878 $1.65 $22,899
Purchase
Common Stock 35,160 $1.54 $54,146
Purchase
Common Stock, $0.0001 par value 10,000 $3.38 $33,800
Purchase
Common Stock, $0.0001 par value 15,500 $3.56 $55,180
Purchase
Common Stock, $0.0001 par value 24,700 $4.15 $102,406

Corvus Pharmaceuticals key executives

Corvus Pharmaceuticals, Inc. executives and other stock owners filed with the SEC: